Cytomegalovirus (CMV) Therapeutics Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

The cytomegalovirus (CMV) therapeutics market share is expected to increase by USD 332.21 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.

This cytomegalovirus (CMV) therapeutics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cytomegalovirus (CMV) therapeutics market segmentation by route of administration (oral, parenteral, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The cytomegalovirus (CMV) therapeutics market report also offers information on several market vendors, including Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Chimerix Inc., Clinigen Group Plc, Exela Pharma Sciences LLC, F. Hoffmann La Roche Ltd., Fortress Biotech Inc., Fresenius SE and Co. KGaA, Genentech Inc., Gilead Sciences Inc., Merck and Co. Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., UbiVac, and VBI Vaccines Inc. among others.

What will the Cytomegalovirus (CMV) Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Cytomegalovirus (CMV) Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Cytomegalovirus (CMV) Therapeutics Market: Key Drivers, Trends, and Challenges

The growing risk factors for CMV is notably driving the cytomegalovirus (CMV) therapeutics market growth, although factors such as low patient adherence may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cytomegalovirus (CMV) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Cytomegalovirus (CMV) Therapeutics Market Driver

One of the key factors driving the global cytomegalovirus (CMV) therapeutics market growth is the growing risk factors for CMV. Population groups with low immunity, such as people with HIV, have the highest prevalence of CMV. However, despite the reduction in the incidence rate, the high prevalence, which is estimated to be approximately 37 million people worldwide, and the limited number of approved therapies create a huge unmet need in the market. The increasing number of hematopoietic stem cell transplant (HSCT) procedures for various indications further increases the risk of CMV infection. The other risk factors for CMV infection include organ transplantation & stem cell transplantation, a weakened immune system due to HIV, and the administration of oral steroids over a period of three months, among others. Chemotherapy is also known to be a risk factor for CMV. All these factors are expected to drive market growth during the forecast period.

Key Cytomegalovirus (CMV) Therapeutics Market Trend

Reformulation of drugs is one of the key CMV therapeutics market trends that is expected to impact the industry positively in the forecast period. To provide treatment options and ensure the high efficacy of their drugs, vendors are developing drugs in more than one form. For instance, Vitrasert, which is offered by Bausch Health, is a drug approved for the treatment of CMV in patients with acquired immunodeficiency syndrome (AIDS). It is available as a prodrug and as an implant. The Vitrasert implant contains ganciclovir in the form of a tablet coated with polyvinyl alcohol and ethylene-vinyl acetate polymers. This is expected to increase patient adherence, which will drive the growth of the market in focus in the coming years.

Key Cytomegalovirus (CMV) Therapeutics Market Challenge

One of the key challenges to the global cytomegalovirus therapeutics market growth is low patient adherence. Currently, the market has only eight approved therapies, which include two generics for the treatment of CMV. The approved therapies are expensive, and the patients must undergo the treatment for a long duration. For instance, patients undergoing treatment using PREVYMIS must use the drug for up to 100 days. The cost of oral PREVYMIS is approximately USD 195 for a day of treatment, and the cost of intravenously administered PREVYMIS is USD 270 in the US. Hence, the total cost of treatment is in the range of USD 19,500 to USD 27,000. Such factors are expected to limit the market growth throughout the forecast period.

This cytomegalovirus (CMV) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the cytomegalovirus (CMV) therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cytomegalovirus (CMV) therapeutics market during the forecast period.

Who are the Major Cytomegalovirus (CMV) Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Astellas Pharma Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Chimerix Inc.
• Clinigen Group Plc
• Exela Pharma Sciences LLC
• F. Hoffmann La Roche Ltd.
• Fortress Biotech Inc.
• Fresenius SE and Co. KGaA
• Genentech Inc.
• Gilead Sciences Inc.
• Merck and Co. Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• UbiVac
• VBI Vaccines Inc.

 

This statistical study of the cytomegalovirus (CMV) therapeutics market encompasses successful business strategies deployed by the key vendors. The cytomegalovirus (CMV) therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

• AstraZeneca Plc - The company offers cytomegalovirus therapeutics through its Cytomegalovirus vaccines. 
• AstraZeneca Plc - In 2022, the company entered an agreement with Scorpion Therapeutics to discover, develop and commercialize novel cancer treatments against undruggable targets. 

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The cytomegalovirus (CMV) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.

Cytomegalovirus (CMV) Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the cytomegalovirus (CMV) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Cytomegalovirus (CMV) Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for cytomegalovirus (CMV) therapeutics in North America. Market growth in this region will be faster than the growth of the market in Rest of the World (ROW).

the high sales of approved therapeutics and the significant prevalence of various types of CMV in countries such as the US will facilitate the cytomegalovirus (CMV) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

 North American countries were among those severely affected by the outbreak of COVID-19 in 2020. The rise in the incidence of COVID-19 across the region influenced various governments to introduce emergency legislation, including restrictions on operational activities in various industries. This led to the shutdown of several manufacturing units, including manufacturing plants that produce drugs for cytomegalovirus treatment, in North America in 2020. However, after the vaccination drive and the lifting of lockdown restrictions, the increase in the number of new and rescheduled medical procedures and treatments, raised the demand for CMV therapeutics. Hence, the increasing adoption of therapeutics will rise in healthcare expenditure. Moreover, the growth in the number of advanced healthcare facilities, and investments by vendors in the CMV therapeutics market are expected to lead to the recovery and growth of the regional market during the forecast period.

What are the Revenue-generating Route of Administration Segments in the Cytomegalovirus (CMV) Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The cytomegalovirus (CMV) therapeutics market share growth by the oral segment will be significant during the forecast period. The presence of F. Hoffmann-La Roche's with its novel drug VALCYTE will drive the market growth through this segment n the coming years. It initially received the required approval for the treatment of CMV retinitis in patients with acquired AIDS and later received marketing approval from the US FDA for the prevention of CMV in patients who have undergone kidney, heart, or kidney-pancreas transplantation.

This report provides an accurate prediction of the contribution of all the segments to the growth of the cytomegalovirus (CMV) therapeutics market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Cytomegalovirus (CMV) Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.44%
Market growth 2022-2026	$332.21 million
Market structure	Fragmented
YoY growth (%)	4.29
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, Denmark, China, and India
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Chimerix Inc., Clinigen Group Plc, Exela Pharma Sciences LLC, F. Hoffmann La Roche Ltd., Fortress Biotech Inc., Fresenius SE and Co. KGaA, Genentech Inc., Gilead Sciences Inc., Merck and Co. Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., UbiVac, and VBI Vaccines Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Cytomegalovirus (CMV) Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive cytomegalovirus (CMV) therapeutics market growth during the next five years
• Precise estimation of the cytomegalovirus (CMV) therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the cytomegalovirus (CMV) therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of cytomegalovirus (CMV) therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch